List of Excipients in Branded Drug BUPRENORPHINE BUCCAL FILM

Generic Drugs Containing BUPRENORPHINE BUCCAL FILM

Company	Ingredient	NDC	Excipient
Alvogen Inc	buprenorphine buccal	47781-471	.ALPHA.-TOCOPHEROL ACETATE
Alvogen Inc	buprenorphine buccal	47781-471	ANHYDROUS CITRIC ACID
Alvogen Inc	buprenorphine buccal	47781-471	CARBOXYMETHYLCELLULOSE SODIUM
Alvogen Inc	buprenorphine buccal	47781-471	FERRIC OXIDE YELLOW
Alvogen Inc	buprenorphine buccal	47781-471	FERROSOFERRIC OXIDE
Alvogen Inc	buprenorphine buccal	47781-471	HYDROXYETHYL CELLULOSE
Alvogen Inc	buprenorphine buccal	47781-471	HYDROXYPROPYL CELLULOSE

What are the Most Frequently-Used Excipients in BUPRENORPHINE BUCCAL FILM?

# Of NDCs	Excipient
1	.ALPHA.-TOCOPHEROL ACETATE
1	ANHYDROUS CITRIC ACID
1	CARBOXYMETHYLCELLULOSE SODIUM
1	FERRIC OXIDE YELLOW
1	FERROSOFERRIC OXIDE
1	HYDROXYETHYL CELLULOSE
1	HYDROXYPROPYL CELLULOSE

Buprenorphine Buccal Film Excipient Strategy and Commercial Opportunities

Last updated: August 3, 2026

Buprenorphine buccal film is a specialized opioid-delivery product in which excipients determine adhesion, drug release, dose uniformity, residence time, taste, manufacturability, and regulatory differentiation. The reference product, BELBUCA, uses a bioerodible mucoadhesive film containing buprenorphine hydrochloride, polycarbophil, hydroxyethyl cellulose, sodium benzoate, citric acid, and, for certain strengths, a color additive [1].

The largest commercial opportunities are in generic buccal-film development, polymer substitution, improved adhesion, taste masking, manufacturing scale-up, abuse-deterrence design, and non-opioid transmucosal delivery platforms. Excipients that change the film's microstructure or release profile can create meaningful formulation and intellectual-property barriers, but they also increase FDA product-specific risk.

What is buprenorphine buccal film and how does it work?

BELBUCA is an FDA-approved buccal film containing buprenorphine hydrochloride for the management of severe and persistent pain requiring an around-the-clock opioid analgesic when alternative treatments are inadequate [1]. The film is placed against the inside of the cheek, where it hydrates, adheres to the mucosa, and releases buprenorphine for transmucosal absorption.

What are the key product attributes?

Attribute	BELBUCA profile
Active ingredient	Buprenorphine hydrochloride
Dosage form	Buccal film
Administration	Applied to the buccal mucosa
Strengths	75, 150, buprenorphine microgram strengths and higher-dose presentations
Route	Transmucosal
Therapeutic category	Opioid analgesic
Controlled-substance classification	Schedule III in the United States
Original FDA approval	2015
Reference sponsor	BioDelivery Sciences International; commercial rights later held by Collegium Pharmaceutical
Delivery technology	Bioerodible, mucoadhesive film

Buprenorphine has high receptor affinity and a pharmacology profile that differs from full mu-opioid agonists. The buccal route avoids substantial gastrointestinal degradation and reduces dependence on swallowing, although product performance remains sensitive to saliva, placement, mucosal condition, food, oral care, and film adhesion [1].

What excipients are used in buprenorphine buccal film?

The listed inactive ingredients in BELBUCA are citric acid, hydroxyethyl cellulose, polycarbophil, sodium benzoate, and a color additive used in certain strengths [1].

What does each excipient do?

Excipient	Primary formulation role	Commercial significance
Polycarbophil	Mucoadhesive polymer and water-swellable matrix component	Supports residence time and adhesion to the buccal mucosa
Hydroxyethyl cellulose	Film-forming, viscosity-modifying, and matrix-forming polymer	Controls mechanical properties, hydration, and drug release
Citric acid	pH modifier and formulation aid	Can influence buprenorphine ionization, solubility, taste, and local microenvironment
Sodium benzoate	Preservative and formulation aid	Supports product stability and may affect taste and regulatory acceptability
Color additive	Product identification and strength differentiation	Helps reduce medication-selection errors across dose strengths

The excipient system is not interchangeable with a conventional tablet formulation. The formulation must balance several competing requirements:

1. Rapid wetting without uncontrolled dissolution.
2. Sufficient adhesion without painful removal.
3. Adequate flexibility during packaging and handling.
4. Uniform drug distribution across a thin film.
5. Controlled erosion and drug release.
6. Acceptable taste and mouthfeel.
7. Low sensitivity to humidity.
8. Compatibility with continuous or semi-continuous manufacturing.

How important are mucoadhesive polymers in buprenorphine film?

Mucoadhesive polymers are the primary technical differentiator in buccal-film development. Polycarbophil and cellulose derivatives create a hydrated polymer network that contacts the mucosal surface and slows film displacement by saliva or tongue movement.

What polymer properties matter most?

Commercially relevant polymer attributes include:

• Molecular weight and substitution level.
• Particle size and dispersion.
• Hydration rate.
• Crosslink density.
• Swelling ratio.
• Adhesive strength.
• Residence time.
• Film tensile strength.
• Elongation and folding resistance.
• Impact on drug diffusion.
• Lot-to-lot viscosity consistency.

A polymer that produces strong initial adhesion may create poor patient experience if it causes mucosal trauma or leaves a difficult-to-remove residue. A polymer with rapid hydration may improve early drug release but reduce residence time. A slower-hydrating matrix may improve retention but delay transmucosal delivery.

Substitution strategies involving hydroxypropyl cellulose, hydroxypropyl methylcellulose, sodium carboxymethylcellulose, polyvinyl alcohol, polyethylene oxide, carbomers, or thiolated polymers could support differentiated products. Each substitute would require a deliberate assessment of drug release, adhesion, film strength, residual film, taste, and local tolerability.

What formulation patents protect buprenorphine buccal film?

The core patent position around BELBUCA has historically focused on buprenorphine-containing mucoadhesive films, film composition, dosage strengths, manufacturing, and methods of treating pain. A prominent patent associated with the product is U.S. Patent No. 8,771,737, which covers buccal-film technology associated with buprenorphine delivery [2].

What is the expected patent-expiration exposure?

Patent category	Representative protection	Commercial impact
Core film composition	Buprenorphine in a mucoadhesive polymer film	Can delay an ANDA relying on the reference formulation
Film architecture	Layered or bioerodible film structures	Creates design-around questions for generic developers
Drug-release control	Polymer ratios, pH, hydration, and erosion characteristics	Can support formulation-specific infringement claims
Method of use	Treatment of chronic pain using buccal buprenorphine	May remain relevant after composition claims expire
Manufacturing	Casting, drying, cutting, packaging, and quality controls	Can create process barriers where claims are narrow

The nominal 20-year patent term for a patent filed from a 2008 priority position would generally place core protection near the late 2020s, subject to patent-term adjustment, terminal disclaimers, patent-family differences, and any applicable pediatric exclusivity. Exact live claims and expiration dates should be read from the current FDA Orange Book and USPTO records rather than inferred from the product launch date [2,3].

What is the Orange Book status of BELBUCA?

BELBUCA is listed in the FDA Orange Book as an approved prescription drug product with patent information submitted by the reference sponsor [3]. Orange Book analysis should separate:

• Active ingredient protection.
• Drug-product or formulation patents.
• Method-of-use patents.
• Patents with pediatric exclusivity.
• Patents subject to litigation or settlement.
• Patents that may be omitted from an ANDA certification because they are not relevant to the proposed labeling.

A generic sponsor typically must evaluate Paragraph I, II, III, or IV certification for each listed patent. A Paragraph IV certification alleges that the listed patent is invalid, unenforceable, or will not be infringed by the proposed generic. The first applicant to submit a qualifying Paragraph IV certification may obtain 180-day generic exclusivity, subject to statutory forfeiture rules [4].

Which companies are challenging or could challenge buprenorphine buccal film?

Potential entrants include established generic manufacturers with oral-film or complex-generics capabilities. Relevant capabilities include controlled-release formulation, solvent casting, hot-melt processing, high-resolution content uniformity testing, and mucoadhesion assessment.

The competitive field is more concentrated than for conventional immediate-release tablets because buccal films require specialized manufacturing and comparative-performance testing. Likely strategic participants include:

• Large generic companies with complex oral products.
• Specialty generic companies with transmucosal delivery experience.
• Contract development and manufacturing organizations with film-casting lines.
• Technology licensors holding mucoadhesive-polymer or oral-film platforms.
• Opioid-focused companies pursuing abuse-deterrent or lower-diversion formulations.

Patent litigation risk depends on the ANDA formulation and the claims asserted. A generic that copies the reference polymer system may face greater formulation-patent exposure. A design-around using different polymers may reduce literal infringement risk but raise FDA equivalence questions.

What generic entry risks exist for BELBUCA?

Generic entry requires more than matching the labeled active ingredient and strength. Key risks include:

Bioequivalence and local performance

Buccal products may have both systemic and local performance characteristics. A generic must demonstrate adequate pharmacokinetic comparability while controlling differences in:

• Adhesion time.
• Film hydration.
• Erosion rate.
• Initial drug release.
• Residual drug after application.
• Buccal absorption.
• Swallowed fraction.
• Saliva-related loss.

A formulation can produce similar plasma exposure while differing in adhesion, mouthfeel, or residual drug. Those differences can affect substitutability, patient acceptance, and post-approval risk.

Manufacturing variability

Thin-film products are sensitive to:

• Drying temperature.
• Residual solvent or water.
• Polymer hydration.
• Casting thickness.
• Die-cutting tolerances.
• Drug crystallization.
• Packaging humidity.
• Roll-to-roll uniformity.

The excipient supplier's grade can affect viscosity, drying behavior, adhesion, and dissolution. A generic sponsor may need tighter incoming specifications than those used for conventional oral solid dosage forms.

Patent and settlement risk

Paragraph IV litigation can delay approval for up to 30 months after the reference sponsor receives notice, unless the litigation is resolved earlier or the court issues a decision [4]. Settlement agreements may provide a licensed entry date, authorized-generic rights, or restrictions on formulation and labeling. The commercial value of an early entry date depends on whether multiple ANDAs launch simultaneously.

What commercial opportunities exist for excipient suppliers?

The most attractive excipient opportunities are not limited to supplying the exact BELBUCA ingredients. Suppliers can create value by improving performance, reducing process variability, or enabling a distinct product profile.

Functionalized mucoadhesive polymers

Potential offerings include polymers with:

• Higher adhesion at lower loading.
• Faster hydration.
• Reduced mouth residue.
• Lower sensitivity to ionic strength.
• Improved adhesion on dry or compromised mucosa.
• Controlled erosion over a defined interval.

Thiolated polymers and catechol-functionalized systems may provide stronger adhesion, but they introduce greater toxicology, stability, and regulatory complexity.

Taste-masking systems

Buprenorphine and polymer matrices can produce bitterness, acidity, or residual mouthfeel. Commercial solutions may include:

• Ion-exchange resins.
• Encapsulation.
• Cyclodextrin complexes.
• Lipid-based taste barriers.
• Polymer-coated drug particles.
• Low-solubility drug carriers.

Taste masking must not materially reduce transmucosal availability or create a delayed-release profile inconsistent with the reference product.

Film-strength and process aids

Excipients that improve tensile strength, reduce brittleness, or widen the manufacturing design space may have value in both branded line extensions and generic products. Plasticizers, including selected polyols or citrate-based materials, can improve flexibility but may increase tackiness, moisture uptake, or drug migration.

Humidity-control packaging

The film and its polymer matrix can be sensitive to moisture. High-barrier unit-dose pouches, desiccant-integrated packaging, and improved heat-seal systems are commercial opportunities linked directly to excipient performance. A formulation that requires less stringent packaging may reduce total cost of goods.

What formulation strategies could support new products?

Higher-dose or lower-dose films

A sponsor could pursue dose strengths outside the reference product range, provided the clinical and regulatory pathway supports the change. Lower-dose films may target opioid tapering or selected pain populations. Higher-dose films face greater safety, diversion, and regulatory scrutiny.

Combination films

A buprenorphine film combined with another active ingredient could target neuropathic pain, inflammatory pain, or opioid-use-disorder treatment. Combination products would require new clinical and interaction data and would not receive the same substitutability treatment as a conventional ANDA.

Abuse-deterrent films

A film could be engineered to resist extraction, rapid dissolution, dose dumping, or manipulation. Potential approaches include insoluble polymer networks, crosslinked matrices, aversive excipients, and tamper-responsive packaging. Abuse-deterrence claims require evidence under FDA guidance and can create a separate patent position [5].

Pediatric and geriatric adaptations

Small, low-dose films with improved taste, reduced adhesion force, and clearer strength identification could support specialty markets. Pediatric use would require a separate clinical and regulatory strategy. Geriatric products could emphasize ease of handling, reduced swallowing burden, and simplified packaging.

How does buprenorphine buccal film compare with competing products?

Product type	Primary advantage	Principal limitation
Buccal film	Avoids swallowing and provides transmucosal delivery	Sensitive to adhesion, taste, and oral conditions
Sublingual tablet or film	Established opioid-use-disorder and pain applications	More swallowing, diversion, and dissolution variability
Transdermal buprenorphine	Long duration and nonoral administration	Slow onset, skin reactions, and dose limitations
Oral extended-release opioid	Familiar manufacturing and prescribing model	Greater gastrointestinal exposure and swallowing dependence
Injectable buprenorphine	High adherence potential	Administration burden and clinical infrastructure

BELBUCA competes most directly with other buprenorphine products and indirectly with non-buprenorphine analgesics. Its commercial positioning depends on dose flexibility, opioid stewardship, prescriber familiarity, payer coverage, and the availability of generic alternatives.

What is the FDA regulatory status and exclusivity position?

BELBUCA received FDA approval under an NDA for chronic pain [1]. It is not a biologic, so biosimilar competition does not apply. Competition would occur through ANDAs or, for materially different products, new 505(b)(2) applications.

FDA exclusivity can include:

• New chemical entity exclusivity, if applicable to the approval basis.
• Three-year exclusivity for certain new clinical investigations.
• Pediatric exclusivity, if granted.
• Orphan-drug exclusivity, if applicable, though this is not the ordinary basis for BELBUCA's chronic-pain indication.
• Patent-based delay from Paragraph IV litigation.

Regulatory exclusivity and patent exclusivity are separate. FDA approval may remain blocked by patent litigation after regulatory exclusivity expires, while an expired patent does not guarantee immediate generic entry if an ANDA remains under review.

What licensing deals and manufacturing partnerships matter?

The asset's commercial history illustrates the importance of platform licensing and specialty-pharma consolidation. BioDelivery Sciences developed BELBUCA using its buccal-film technology, and Collegium acquired BioDelivery Sciences in 2022, bringing BELBUCA into a broader pain-product portfolio [6].

For future entrants, the main licensing opportunities are:

• Mucoadhesive film technology.
• Buccal polymer libraries.
• Taste-masking systems.
• Abuse-deterrent matrices.
• High-throughput film casting.
• Unit-dose moisture-barrier packaging.
• Reference-product analytical methods.

A licensing transaction should allocate ownership of formulation patents, process improvements, analytical methods, regulatory data, manufacturing know-how, and rights to improvements. Excipient suppliers that provide only commodity material face lower margins than suppliers offering a qualified grade with process knowledge and regulatory support.

How strong is the patent estate for buprenorphine buccal film?

The estate is strongest where claims combine the active ingredient with specific film architecture, polymer composition, dosage range, release behavior, or manufacturing parameters. Broad claims covering any buprenorphine oral film are more vulnerable to validity and prior-art challenges than claims tied to measurable formulation attributes.

Patent-strength indicators

Indicator	Effect on competitive strength
Narrow polymer-ratio claims	Stronger against close copies, easier to design around
Broad buccal-film claims	Wider coverage, greater prior-art exposure
Claims tied to clinical outcomes	Potentially valuable but difficult to prove in litigation
Manufacturing claims	Useful where process is difficult to detect
Method-of-use claims	Can restrict labeling but may not block skinny-label entry
Multiple patent families	Increase litigation cost and delay risk
Expiring core patents	Shift value toward manufacturing, brand, and supply advantages

The most defensible formulation strategy for a follow-on product is a demonstrable technical improvement that also creates a distinct claim set. Merely replacing one cellulose derivative with another may not produce sufficient commercial or patent value unless the change improves adhesion, taste, stability, release, or manufacturing economics.

What revenue exposure and launch scenarios should investors monitor?

BELBUCA revenue is exposed to three principal events:

1. ANDA approval without immediate commercial launch.
2. A first generic launch under exclusivity or settlement rights.
3. Multiple generic launches after core patent barriers weaken.

A single generic may produce a moderate price decline if substitution remains limited. Several generic entrants typically create faster erosion through payer substitution and pharmacy-level switching. An authorized generic or settlement-backed launch can accelerate erosion while preserving some supply-chain control for the reference sponsor.

The most important indicators are:

• FDA ANDA approvals.
• Paragraph IV notices.
• District-court and Federal Circuit decisions.
• Orange Book patent changes.
• Abbreviated labeling or skinny-label activity.
• Collegium's product-level revenue disclosures.
• Wholesale acquisition price changes.
• Formulary tier movement.
• Generic manufacturing capacity.

Key Takeaways

• BELBUCA relies on a polymer-based bioerodible mucoadhesive film rather than a conventional tablet matrix.
• Polycarbophil and hydroxyethyl cellulose are central to adhesion, hydration, mechanical integrity, and release behavior.
• The strongest commercial opportunities are functionalized polymers, taste masking, humidity-resistant packaging, abuse-deterrent films, and complex-generic development.
• Generic entry is constrained by formulation similarity, local buccal performance, manufacturing variability, Orange Book patents, and Paragraph IV litigation.
• Biosimilar competition is not relevant because buprenorphine buccal film is a small-molecule drug.
• Patent value is concentrated in film composition, polymer architecture, dosage ranges, release behavior, use claims, and manufacturing methods.
• Collegium's acquisition of BioDelivery Sciences made BELBUCA part of a broader specialty-pain portfolio.
• Excipient suppliers with qualified grades and technical support have greater commercial leverage than commodity suppliers.
• Core patent protection is expected to move toward the late 2020s, but live expiration dates must be determined patent by patent from current USPTO and Orange Book records.

FAQs About Buprenorphine Buccal Film Excipients and Commercial Strategy

Can hydroxyethyl cellulose be replaced in a generic buprenorphine film?

Yes, but replacement can affect film strength, hydration, adhesion, drug release, taste, and bioequivalence. The substitute polymer must be supported by comparative formulation and performance data.

Is polycarbophil a critical excipient for BELBUCA?

Polycarbophil is a major mucoadhesive component of the labeled formulation. A generic developer may attempt to replace it, but the change can alter residence time and local drug absorption.

Can a company launch a buprenorphine buccal film under a 505(b)(2) application?

Potentially. A 505(b)(2) pathway may be appropriate for a materially different strength, formulation, delivery system, or indication that cannot rely fully on the reference product's data. Patent and exclusivity certifications still require analysis.

Does buprenorphine buccal film require an abuse-deterrent label?

No. Conventional BELBUCA approval does not automatically establish an FDA abuse-deterrent claim. A sponsor seeking that claim would need product-specific abuse-deterrence evidence.

What is the highest-value excipient innovation for buprenorphine film?

The highest-value opportunity is usually a polymer or matrix system that improves adhesion and taste while preserving rapid, reproducible transmucosal release and reducing humidity sensitivity. Such an improvement can support both product differentiation and new patent claims.

References

1. U.S. Food and Drug Administration. (2024). BELBUCA (buprenorphine hydrochloride) buccal film prescribing information.
2. U.S. Patent and Trademark Office. (2014). U.S. Patent No. 8,771,737, buccal film compositions and methods.
3. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Refuse-to-receive standards and Paragraph IV certification framework.
5. U.S. Food and Drug Administration. (2015). General principles for evaluating abuse-deterrent formulations of opioid drugs.
6. Collegium Pharmaceutical, Inc. (2022). Current report and acquisition materials relating to BioDelivery Sciences International.